Antidepressant No Help for Autism Behaviors
Celexa for Autism No More
Effective Than Placebo at Reducing Repetitive Behaviors, Study Shows
By Kathleen
Doheny
WebMD Health News
Latest Mental Health News
Reviewed by Louise Chang, MD
June 1, 2009 --The antidepressant
Celexa, often prescribed for children with
autism and autism spectrum disorders (ASD) to reduce repetitive behaviors, works
no better than a placebo, according to a new study.
Even worse, the medication was more likely than the placebo to produce
adverse side effects such as increased energy, impulsiveness, and decreased
concentration, the researchers found.
The study findings were a surprise, says the study's lead author Bryan H.
King, MD, director of child and adolescent psychiatry at Seattle Children's
Hospital and professor and vice-chairman of psychiatry at the University of
Washington School of Medicine. "We were fully expecting to demonstrate the value
of this drug," he tells WebMD.
"A medication that we thought would be helpful for these repetitive behaviors
was no better than placebo," he says. "That calls into question how or if we
should use [Celexa] or even related medications for this purpose."
Repetitive behaviors in children with autism or ASD include asking the same
question over and over; repeating body movements, such as swaying or spinning;
or insisting on inflexible daily routines, such as taking the same route to
school.
The study is published in the Archives of General Psychiatry and was funded
by the National Institutes of Health.
Celexa for Autism: Study Background
Although antidepressant drugs such as Celexa aren't approved by the FDA to
treat the repetitive behaviors of children with autism or ASD, they are widely
prescribed "off-label", a common and legal practice.
"Surveys suggest about a third of the kids with autism
treated with medication are on one of the SSRIs for a variety of symptoms," King
says. SSRIs, or selective serotonin reuptake inhibitors, are a family of drugs
such as Celexa that work by increasing the level of the brain chemical
serotonin, associated with mood and behavior. The SSRIs have been shown to help
reduce repetitive behavior in children with obsessive-compulsive disorder, King says.
Celexa for
Autism: Study Details
King and his colleagues evaluated 149 children, aged 5 to 17, all diagnosed
with autism or other ASD and being treated at six academic medical centers
across the country. They were enrolled from April 2004 through October 2006 and
randomly assigned to get either placebo or an average of 16.5 milligrams a day
of liquid Celexa.
"Most had autism," King says. All the children had at least a moderate level
of repetitive behaviors. The researchers focused on how well the drug reduced
these behaviors, evaluating the results by using commonly used scales to show
improvement in the behaviors.
Celexa for Autism: Study Results
After 12 weeks, about one of three children in each group -- 32.9% of those
on Celexa and 34.2% of those on placebo -- showed fewer or less severe
repetitive symptoms.
Side effects were more common in the children taking Celexa, the researchers
found. Those on Celexa were more likely to have increased energy levels,
impulsiveness, decreased concentration, hyperactivity, mechanical repetition of
the same movement or posture, and sleep problems.
Treating Repetitive Behaviors:
Other Opinions
In a commentary accompanying the study, Fred R. Volkmar,
MD, of the Yale Child Study Center, speculates that the findings may change the
widespread practice of prescribing antidepressants for children with autism and ASD.
Although the researchers note in the report of the study that different
results might have been obtained with larger numbers of children, Volkmar says
the King study is believed to be the largest such trial of the SSRIs in children
with autism or ASD.
''It's important to realize the door is not necessarily closed on SSRIs,''
Volkmar tells WebMD. Other SSRI drugs may be found to help, says Volkmar, the
Irving B. Harris Professor at Yale.
The study finding also suggests that researchers should explore why the SSRI
drugs seem to work well overall in adults but not always in children, he says.
Forest Laboratories, which makes Celexa, says in a statement, "Forest
Laboratories was not involved in this study and therefore cannot provide
comment."
The results are ''disappointing," says Thomas Insel, MD, director of the
National Institute of Mental Health. "The bottom line is, it doesn't sound like
the medication is any better than placebo."
Because repetitive behaviors can be a significant problem, he says, "The
question is, is there something else that can be used?"
Because Celexa didn't work for the autism-related repetitive behaviors but
does work for those associated with obsessive-compulsive disorder, Insel says
the findings may yield a clue that the behaviors are fundamentally different in
some way.
Another expert, Geraldine Dawson, PhD, chief science
officer for Autism
Speaks, an advocacy and research organization, agreed that the study suggests
the "underlying biology" is different for obsessive-compulsive disorder and
autistic behaviors. The study finding "really does suggest that this drug is not
going to be helpful for repetitive behaviors," she says.
Earlier this year, Autism Speaks released initial results of its study of
another SSRI, Prozac, finding it also not effective in reducing repetitive
behaviors compared to placebo. However, the study is continuing.
Implications
for Treatment & Advice for Parents
Although other SSRIs may result in a different effect, King says, there is
not enough research right now to make a clear recommendation about SSRIs as a
class of drugs to treat repetitive behaviors associated with autism.
And what should parents do if their child is doing well on an SSRI prescribed
to reduce repetitive behaviors? "It's very hard to argue with improvement," King
tells WebMD. "If a child is taking an antidepressant and seems to be doing very
well, you do not want to summarily discontinue treatment for that child."
But he does suggest that parents talk to their child's health care provider
and consider the possibility of taking the child off the drug to see if the
benefit remains. The improved behavior may not be tied to the medication, King
says.
Repetitive behaviors related to autism can have an "ebb and flow," Insel
says. Children may have been enrolled in the trial when their symptoms are
somewhat worse and their symptoms may have improved over time even without the
medication.
SOURCES:
Bryan H. King, MD, director of child and adolescent psychiatry, Seattle
Children's Hospital and professor and vice chair of psychiatry, University of
Washington School of Medicine.
Fred R. Volkmar, MD, of the Yale Child Study Center and the Irving B. Harris
Professor, Yale University.
King, B. Archives of General Psychiatry, June 2009; vol 66: pp 583-590.
Volkmar, F. Archives of General Psychiatry, June 2009; vol 66: pp
581-582.
Thomas R. Insel, MD, director, National Institute of Mental Health, Bethesda,
Md.
Geraldine Dawson, chief science officer, Autism Speaks, New York, N.Y.
Patricia Li, spokeswoman, Forest Laboratories.
© 2009 WebMD, LLC. All rights reserved.